Control Bionics Ltd Net Assets
Control Bionics Ltd net assets. Based on the latest financial reports, Control Bionics Ltd (CBL) has net assets worth AU$6.31 Million AUD (≈ $4.47 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$9.05 Million ≈ $6.40 Million USD) and total liabilities (AU$2.73 Million ≈ $1.93 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CBL year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$6.31 Million |
| % of Total Assets | 69.77% |
| Annual Growth Rate | -24.96% |
| 5-Year Change | -47.06% |
| 10-Year Change | -97.76% |
| Growth Volatility | 96.82 |
Net Assets of Control Bionics Ltd (2014–2025)
Net assets of Control Bionics Ltd from 2014 to 2025. This chart illustrates how Control Bionics Ltd's net assets have evolved over time, based on quarterly financial data. See Control Bionics Ltd balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Control Bionics Ltd (2014–2025)
The table below shows the annual net assets of Control Bionics Ltd from 2014 to 2025. For live market cap and overall valuation, see Control Bionics Ltd (CBL) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | AU$6.31 Million ≈ $4.47 Million |
+14.60% |
| 2024-12-31 | AU$5.51 Million ≈ $3.90 Million |
-12.11% |
| 2023-12-31 | AU$6.27 Million ≈ $4.43 Million |
-11.92% |
| 2022-12-31 | AU$7.12 Million ≈ $5.04 Million |
-40.32% |
| 2021-12-31 | AU$11.92 Million ≈ $8.44 Million |
-30.53% |
| 2020-12-31 | AU$17.16 Million ≈ $12.14 Million |
-14.72% |
| 2019-12-31 | AU$20.13 Million ≈ $14.24 Million |
+298.26% |
| 2018-12-31 | AU$5.05 Million ≈ $3.58 Million |
-17.02% |
| 2017-12-31 | AU$6.09 Million ≈ $4.31 Million |
-97.84% |
| 2016-12-31 | AU$281.41 Million ≈ $199.11 Million |
+54.91% |
| 2015-12-31 | AU$181.66 Million ≈ $128.54 Million |
+22.29% |
| 2014-12-31 | AU$148.55 Million ≈ $105.11 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Control Bionics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 196.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Control Bionics Ltd Net Assets Breakdown (December 2025)
Control Bionics Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$46.14 Million | 730.93% |
| Other Comprehensive Income | AU$2.82 Million | 44.73% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$6.31 Million | 100.00% |
Control Bionics Ltd Competitors by Market Cap
The table below lists competitors of Control Bionics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SANUWAVE Health, Inc. Common Stock
NASDAQ:SNWV
|
$18.83 Million |
|
Bannari Amman Spinning Mills Limited
NSE:BASML
|
$18.83 Million |
|
Ordinary Fully Paid Deferred Settlement
AU:88EDA
|
$18.83 Million |
|
Prakit Holdings Public Company Limited
BK:PRAKIT
|
$18.84 Million |
|
Catenon S.A
MC:COM
|
$18.83 Million |
|
Murudeshwar Ceramics Limited
NSE:MURUDCERA
|
$18.82 Million |
|
PERFORMANCE SHIPP.
F:DS2
|
$18.82 Million |
|
Lipidor Ab
ST:LIPI
|
$18.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Control Bionics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,508,725 to 6,312,928, a change of 804,203 (14.6%).
- Net loss of 7,265,603 reduced equity.
- Other comprehensive income increased equity by 2,292,728.
- Other factors increased equity by 5,777,078.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-7.27 Million | -115.09% |
| Other Comprehensive Income | AU$2.29 Million | +36.32% |
| Other Changes | AU$5.78 Million | +91.51% |
| Total Change | AU$- | 14.60% |
Book Value vs Market Value Analysis
This analysis compares Control Bionics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.88x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.07x to 2.88x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | AU$0.68 | AU$0.05 | x |
| 2015-12-31 | AU$1.07 | AU$0.05 | x |
| 2016-12-31 | AU$1.26 | AU$0.05 | x |
| 2017-12-31 | AU$0.07 | AU$0.05 | x |
| 2018-12-31 | AU$0.05 | AU$0.05 | x |
| 2019-12-31 | AU$0.22 | AU$0.05 | x |
| 2020-12-31 | AU$0.19 | AU$0.05 | x |
| 2021-12-31 | AU$0.13 | AU$0.05 | x |
| 2022-12-31 | AU$0.07 | AU$0.05 | x |
| 2023-12-31 | AU$0.04 | AU$0.05 | x |
| 2024-12-31 | AU$0.02 | AU$0.05 | x |
| 2025-12-31 | AU$0.02 | AU$0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Control Bionics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -115.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -152.42%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.43x
- Recent ROE (-115.09%) is below the historical average (-45.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 18.32% | 14.29% | 0.33x | 3.84x | AU$15.12 Million |
| 2016 | 10.16% | 9.19% | 0.27x | 4.11x | AU$462.56K |
| 2017 | -15.97% | -120.74% | 0.13x | 1.04x | AU$-1.58 Million |
| 2018 | -38.22% | -247.19% | 0.14x | 1.07x | AU$-2.44 Million |
| 2019 | -5.00% | -32.44% | 0.15x | 1.02x | AU$-3.02 Million |
| 2020 | -20.69% | -86.85% | 0.22x | 1.07x | AU$-5.27 Million |
| 2021 | -51.24% | -135.72% | 0.34x | 1.13x | AU$-7.30 Million |
| 2022 | -78.78% | -99.80% | 0.65x | 1.22x | AU$-6.35 Million |
| 2023 | -94.35% | -110.52% | 0.59x | 1.44x | AU$-6.54 Million |
| 2024 | -110.89% | -99.41% | 0.75x | 1.49x | AU$-6.66 Million |
| 2025 | -115.09% | -152.42% | 0.53x | 1.43x | AU$-7.90 Million |
Industry Comparison
This section compares Control Bionics Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $41,367,714
- Average return on equity (ROE) among peers: -25.62%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Control Bionics Ltd (CBL) | AU$6.31 Million | 18.32% | 0.43x | $18.83 Million |
| 4DMEDICAL Ltd (4DX) | $83.36 Million | -25.70% | 0.11x | $925.65 Million |
| Adherium Ltd (ADR) | $34.53 Million | -3.63% | 0.08x | $2.37 Million |
| Aroa Biosurgery Ltd (ARX) | $32.56 Million | 0.00% | 0.25x | $130.04 Million |
| Atomo Diagnostics Ltd (AT1) | $30.09 Million | -20.01% | 0.07x | $9.58 Million |
| Avita Medical Inc (AVH) | $124.47 Million | -31.47% | 0.16x | $188.51 Million |
| Anteris Technologies Global Corp (AVR) | $14.35 Million | -159.65% | 1.05x | $561.92 Million |
| Cardiex Ltd (CDX) | $9.38 Million | -55.24% | 0.22x | $13.23 Million |
| Compumedics Ltd (CMP) | $11.48 Million | 23.76% | 0.87x | $33.92 Million |
| Cochlear Ltd (COH) | $32.09 Million | 41.39% | 1.15x | $7.19 Billion |
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more